Quest Magazine

Reactivated Virus May Contribute to ALS

New research suggests that the DNA of a normally dormant virus may be playing a role in causing amyotrophic lateral sclerosis (ALS).

If the findings are confirmed, they could ultimately have implications for treatment of the disease.

About the HERV-K virus

'Cloud-Enhanced' Accessibility: Competition Seeks Visionaries

The Federal Communications Commission wants to know: What’s your vision for using “cloud computing” to create new opportunities for people with disabilities?

The FCC is co-sponsoring the competition “Lifted by the Cloud: Visions of Cloud-Enhanced Accessibility,” and asking participants to create short multimedia presentations showing “what could be possible using the computing and communication power now available via the Internet.”

ALS Research Briefs

Loss of TDP43's normal function could be ALS contributor

Legislative Briefs: International Rare Disease Day and More

International Rare Disease Day 2011

Monday, February 28, 2011, marks the fourth annual International Rare Disease Day, in which hundreds of patient organizations from more than 40 countries conduct awareness-raising activities around the slogan “Rare but Equal.” The worldwide event is an effort to draw attention to rare diseases and the millions of people who are affected by them — including all those covered by the MDA umbrella. 

Research Briefs: CMS, DMD, LGMD, Pompe, Stem Cells

Congenital myasthenic syndromes

A multinational team of scientists has identified mutations in the gene for glutamine-fructose-6-phosphate transaminase 1 (GFPT1) as responsible for some forms of a congenital myasthenic syndrome (CMS).

Unconventional Pianist with CMT Hopes to Raise a Million

Amble playing a "techno music" piece that he composed when he was 9.

Research Briefs: CMT, CMS, DMD/BMD, FA, Pompe disease, SBMA

UCLA Researcher Receives MDA Grant to Develop DMD Drug

A new MDA translational research grant for $476,465 over three years will allow Carmen Bertoni at the University of California, Los Angeles (UCLA) to develop RTC13, an experimental compound designed to treat Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) caused by a specific type of flaw in the gene for the muscle protein dystrophin.

Eight New Grants Bolster MDA's Battle Against ALS

MDA has awarded eight new grants totaling nearly $2.5 million to fund research projects focused on uncovering the causes of, and developing therapies for, ALS. The effective start date for the grants was Feb. 1, 2011.

MDA Awards $13.5 Million in Research Grants

The Muscular Dystrophy Association has awarded 44 grants totaling $13.5 million to support research efforts aimed at advancing understanding of disease processes and uncovering new strategies for treatments and cures of muscular dystrophy and the more than 40 other diseases in the Association’s program.

The new grants were reviewed by MDA’s Scientific and Medical Advisory Committees, and approved by MDA’s Board of Directors at its December meeting.